From: Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD
 | Never smoker controls, n = 11 | Ex-smoker controls, n = 44 | COPD, n = 88 |
---|---|---|---|
Age | 58 ± 5.9 | 61 ± 5.4 | 63 ± 8E,N |
Male, (n)% | (3) 27.3 | (22) 50 | (46) 52.3 |
Pack years* | 0 ± 0 | 15.6 ± 13.3 | 35.0 ± 16.1E,N |
Smoking status, (n)%§ | - | - | Ex-smoker (64) 72.7 Current smoker (18) 20.5 |
BMI, kg/m2 | 26.9 ± 4.0 | 27.52 ± 4.0 | 26.1 ± 5.2 |
FEV1% predicted | 114.5 (104.0-120.0 | 122.1 (112.0-133.0) | 45.50 (32.3-61.0)E,N |
FEV1/VC% | 79.2 (74.6-82.3) | 78.9 (75.2-82.5) | 51.9 (38.3-63.3)E,N |
DLCO% predicted | - | - | 51.46 (42.4-73.19) |
LTOT (n) | - | - | 16 |
Triglycerides, mg/dl | 92.2 (85.1-109.0) | 93.0 (71.8-135.6) | 100.1 (84.2-136.9) |
HDL, mg/dl | 69.1 ± 14.3 | 68.5 ± 20.5 | 75 ± 27 |
CRP, mg/L | 0.6 (0.1-0.9) | 0.7 (0.3-1.8) | 3.4 (1.7-8.5)E,N |
Medication use | |||
Long/short acting muscarinic receptor antagonist (n)% | Â | Â | 63 (73.9) |
LABA, (n)% | Â | Â | 40 (45.5) |
SABA, (n)% | Â | Â | 23 (26.1) |
LABA + inhaled corticosteroids, (n)% | Â | Â | 54 (61.4) |
Inhaled corticosteroid, (n)% | Â | Â | 11 (12.5) |
Oral corticosteroid, (n)% | Â | Â | 17 (19.3) |
N- acetylcysteine, (n)% | Â | Â | 9 (10.2) |
Statins, (n)% | Â | Â | 22 (20.6) |